Summit Therapeutics IncSMMT
Price$16.69

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$1.1BTTM through 30 Jun 2026
Free Cash Flow -$459.8MTTM through 30 Jun 2026

Margins

Current

Returns

-220.9%ROE
-186.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio5.88x
Net Debt-$598.7Mnet cash position
Cash & Equivalents$419.4M

Quality Metrics

Altman Z-Score62.03
Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'19'20'21'22'23'24
FY2024: $0
Diluted EPS-$1.11TTM
'19'20'21'22'23'24'25
FY2025: $-1.44

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Oncology Drug Development$0
View details

Heavy clinical trial spending is expected to continue as Phase III trials (HARMONi-3, HARMONi-7, and HARMONi-GI3) progress.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.